Overview

Cancer is a leading cause of death across the globe. According to the World Health Organization (WHO), cancer accounted for 7.6 million deaths—about 13 percent of all deaths—worldwide in 2008, with that number expected to grow to 12 million deaths by 2030. Pharmaceutical and biotechnology companies are working to translate scientific breakthroughs into new treatments to address this critical unmet need. According to Decision Resources, the targeted cancer drug market will double in value, from $25 billion in 2008 to $51 billion in 2015.

VBL Therapeutics is committed to developing first-in-class treatments for cancer that will offer new hope to patients and their families. Leveraging our innovative, proprietary, award-winning VTS™ (Vascular Targeting System) platform technology, we have discovered and progressed VB-111, highly-targeted anti-angiogenic biological agent for the treatment of cancer into clinical trials. VBL is in Phase 2 clinical trials for VB-111 in thyroid cancer and glioblastoma.